Full-Time

Manager/Sr. Manager

Communications

Posted on 8/30/2024

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

No salary listed

Mid

Lexington, MA, USA

Category
Public Health
Biology & Biotech
Requirements
  • Minimum of 3 years of communications experience in the biopharma industry, either in-house at a biopharmaceutical company or at an agency
  • Bachelor's degree required, preferably in science, business, or related field
  • Excellent communication skills, both verbal and written, with the ability to articulate complex concepts clearly and concisely to diverse audiences
  • Ability to thrive in a fast-paced, dynamic environment, with a high level of adaptability, flexibility, and resilience to changing priorities and business needs.
  • Ability to collaborate effectively with cross-functional teams at all levels
  • Strong attention to detail and a commitment to accuracy
  • Ability to work independently and use sound judgement and decision-making skills
  • Candidates will be assessed for the level of the role according to their individual experience and capabilities
Responsibilities
  • Lead all digital and social media efforts; create and/or oversee creation and review of all content.
  • Support corporate communications efforts such as press releases, media outreach, and thought leadership, working with external PR firm.
  • Support investor communications materials such as earnings releases, corporate decks, earnings call materials, etc., working with external IR firm.
  • Own visual brand; lead coordination of cohesive use of logo and visual design elements across all departments and materials.
  • Support evolution of corporate narrative working with Chief Corporate Affairs Officer and brand/design firm.
  • Lead strategy and execution for internal communications, including Town Halls, Leadership Communications, Intranet, Newsletter, TVs, and other events/channels.
  • Own creation of all internal communications content (and/or oversee all content creation with agency partner and internal partners, such as HR team).
  • Support corporate-level patient advocacy, including budget/requests for funding, partnering with clinical/medical teams.

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like ALS. Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform that allows for the delivery of genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions and emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Novartis could expand treatment options for SMA and neurological conditions.
  • Great Point Partners' $12.67 million investment shows confidence in Voyager's growth potential.
  • Selection of GBA1 program candidate with Neurocrine highlights progress in Parkinson's treatment.

What critics are saying

  • Potential securities fraud investigation may lead to legal and financial issues.
  • Novartis collaboration may face challenges if clinical trials don't meet expectations.
  • New CMO from Biogen might cause strategic shifts disrupting ongoing projects.

What makes Voyager Therapeutics unique

  • Voyager focuses on CNS diseases needing new therapies, like Parkinson's and ALS.
  • Their proprietary AAV capsid platform shows promise in crossing the blood-brain barrier.
  • Voyager's patient-first philosophy emphasizes transformative treatments and innovative delivery methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

6%

2 year growth

11%
Markets Gone Wild
Feb 25th, 2025
Pomerantz Law Firm Investigates Potential Lawsuit Against Voyager Therapeutics: What Does This Mean for Individual Investors?

In a recent press release dated February 25, 2025, Pomerantz LLP announced that it is investigating potential securities fraud claims on behalf of investors of Voyager Therapeutics, Inc. (Voyager or the Company).

Stock Titan
Feb 25th, 2025
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.

SMA News Today
Jan 3rd, 2025
Top 10 SMA news stories of 2024

At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.

MarketBeat
Sep 24th, 2024
Great Point Partners LLC Invests $12.67 Million in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).

CityBiz
Jun 13th, 2024
Voyager Therapeutics Appoints Nathan Jorgensen as Chief Financial Officer

Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.

INACTIVE